Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791877 | 0.95 | OPRM1 (0.40) | OPRM1OPRL1FABP4FFAR3CYP2C19 | |
| SCHEMBL9781693 | 0.91 | OPRM1 (0.42) | OPRM1OPRL1FABP4FFAR3 | |
| SCHEMBL15116666 | 0.79 | OPRM1 (0.37) | OPRM1OPRL1 | |
| SCHEMBL2090673 | 0.78 | FFAR3 (0.38) | OPRM1OPRL1FABP4FFAR3CYP2C19 | |
| Hydrochloric Acid SCHEMBL6601346 | 0.76 | FFAR3 (0.36) | OPRM1OPRL1FABP4FFAR3CYP2C19 | |
| SCHEMBL2089260 | 0.76 | CYP2C19 (0.38) | OPRM1OPRL1FABP4FFAR3CYP2C19 | |
| SCHEMBL20221333 | 0.76 | OPRM1 (0.35) | OPRM1OPRL1 | |
| SCHEMBL30282214 | 0.76 | FABP4 (0.37) | OPRM1OPRL1FABP4FFAR3 | |
| SCHEMBL23832502 | 0.74 | CYP2C19 (0.37) | FFAR3CYP2C19 | |
| SCHEMBL20738603 | 0.73 | OPRM1 (0.39) | OPRM1OPRL1FFAR3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |